ArticlePloS one2025
Brain volumetric reductions in patients with thrombotic thrombocytopenic purpura.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The quiet brain injury in thrombotic thrombocytopenic purpura: Are we missing the warning signs?British journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by a deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). The recognition of increased morbidity and mortality in patients after recovery suggests that TTP may become a chronic disease with possible multiple adverse outcomes throughout life. Neurological disorders may occur in the acute phase of TTP due to several pathophysiological mechanisms. These mechanisms include the formation of microvascular thrombosis in capillaries or small arteries of the central nervous system (CNS), leading to transient or permanent ischemic brain damage. However, the causes underlying chronic neurological involvement in TTP are not fully understood, particularly in long-term survivors. Therefore, the aim of this study is to evaluate brain volumetry in TTP patients in remission and to correlate it with the neurological involvement associated with the disease. METHODOLOGY: The study cohort includes 16 consecutive patients diagnosed with TTP between 1995 and 2016 at the Hospital de Clinicas, Universidade Estadual de Campinas (HC-UNICAMP), in Brazil. We performed MRI of the patients' skull. Brain volume and parts of the central nervous system were analyzed and segmented using FreeSurfer.
resultsThe CNS volumetry of 16 TTP survivors was analyzed and compared with that of 20 age- and sex-matched controls. TTP survivors showed a reduction in intracranial volume (1,019 cubic liters (L3)) compared to the control group (1,280 L3), with a P value of 0.0003. The nucleus accumbens showed a significant reduction on the left side (469 mm3 in TTP survivors X 605 mm3 in controls, P = 0.02). The cerebellar cortex showed a reduction on the right side (44176.50 mm3 in TTP survivors X 47283.15 mm3 in control group, P = 0.05) and on the left side.
conclusionOur study demonstrated a significant reduction in brain and nucleus accumbens volume in patients with TTP compared with a healthy control group. These findings suggest a possible lasting impact of TTP on the CNS and highlight the importance of continued monitoring and intervention to reduce neurological complications in patients after the acute phase of the disease. Future studies are needed to validate our results and elucidate the mechanisms underlying the brain changes observed in patients with TTP. Our findings provide valuable information for developing more effective treatment strategies and improving the quality of life of patients with TTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.